The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury

Hiroyuki Seki, Koichi Fukunaga, Makoto Arita, Hiroyuki Arai, Hiroki Nakanishi, Ryo Taguchi, Taku Miyasho, Rina Takamiya, Koichiro Asano, Akitoshi Ishizaka, Junzo Takeda, Bruce D. Levy

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Whereas pneumonia is the most common cause of death and disability worldwide, most cases of pneumonia spontaneously resolve. Mechanisms that promote pneumonia resolution remain to be determined. Resolvin E1 (RvE1) is an endogenous mediator that displays proresolving actions in sterile inflammation. In this study, we developed a new model of aspiration pneumonia to evaluate the effect of RvE1 on acute lung injury caused by acid aspiration and subsequent bacterial challenge. Mice received hydrochloric acid into the left lung followed by the enteric pathogen Escherichia coli. I.v. administration of RvE1 (∼0.005 mg/kg) prior to acid injury selectively decreased lung neutrophil accumulation by 55% and enhanced clearance of E. coli. RvE1 significantly decreased lung tissue levels of several proinflammatory chemokines and cytokines, including IL-1β, IL-6, HMGB-1, MIP-1α, MIP-1β, keratinocyte-derived chemokine, and MCP-1, in a manner independent of the anti-inflammatory mediators IL-10 and lipoxin A4. In addition, animals treated with RvE1 had a marked improvement in survival. These findings in experimental aspiration pneumonia have uncovered protective roles for RvE1 in pathogen-mediated inflammation that are both anti-inflammatory for neutrophils and protective for host defense, suggesting that RvE1 represents the first candidate for a novel therapeutic strategy for acute lung injury and pneumonia that harnesses natural resolution mechanisms.

Original languageEnglish
Pages (from-to)836-843
Number of pages8
JournalJournal of Immunology
Volume184
Issue number2
DOIs
Publication statusPublished - 2010 Jan 15

Fingerprint

Bacterial Pneumonia
Acute Lung Injury
Anti-Inflammatory Agents
Pneumonia
Aspiration Pneumonia
Lung
Neutrophils
HMGB Proteins
Escherichia coli
Inflammation
Acids
Hydrochloric Acid
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
Interleukin-1
Chemokines
Interleukin-10
Cause of Death
Interleukin-6
Cytokines
Wounds and Injuries

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. / Seki, Hiroyuki; Fukunaga, Koichi; Arita, Makoto; Arai, Hiroyuki; Nakanishi, Hiroki; Taguchi, Ryo; Miyasho, Taku; Takamiya, Rina; Asano, Koichiro; Ishizaka, Akitoshi; Takeda, Junzo; Levy, Bruce D.

In: Journal of Immunology, Vol. 184, No. 2, 15.01.2010, p. 836-843.

Research output: Contribution to journalArticle

Seki, H, Fukunaga, K, Arita, M, Arai, H, Nakanishi, H, Taguchi, R, Miyasho, T, Takamiya, R, Asano, K, Ishizaka, A, Takeda, J & Levy, BD 2010, 'The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury', Journal of Immunology, vol. 184, no. 2, pp. 836-843. https://doi.org/10.4049/jimmunol.0901809
Seki, Hiroyuki ; Fukunaga, Koichi ; Arita, Makoto ; Arai, Hiroyuki ; Nakanishi, Hiroki ; Taguchi, Ryo ; Miyasho, Taku ; Takamiya, Rina ; Asano, Koichiro ; Ishizaka, Akitoshi ; Takeda, Junzo ; Levy, Bruce D. / The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. In: Journal of Immunology. 2010 ; Vol. 184, No. 2. pp. 836-843.
@article{f17e9c450b3247c49bafff9acc6123a9,
title = "The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury",
abstract = "Whereas pneumonia is the most common cause of death and disability worldwide, most cases of pneumonia spontaneously resolve. Mechanisms that promote pneumonia resolution remain to be determined. Resolvin E1 (RvE1) is an endogenous mediator that displays proresolving actions in sterile inflammation. In this study, we developed a new model of aspiration pneumonia to evaluate the effect of RvE1 on acute lung injury caused by acid aspiration and subsequent bacterial challenge. Mice received hydrochloric acid into the left lung followed by the enteric pathogen Escherichia coli. I.v. administration of RvE1 (∼0.005 mg/kg) prior to acid injury selectively decreased lung neutrophil accumulation by 55{\%} and enhanced clearance of E. coli. RvE1 significantly decreased lung tissue levels of several proinflammatory chemokines and cytokines, including IL-1β, IL-6, HMGB-1, MIP-1α, MIP-1β, keratinocyte-derived chemokine, and MCP-1, in a manner independent of the anti-inflammatory mediators IL-10 and lipoxin A4. In addition, animals treated with RvE1 had a marked improvement in survival. These findings in experimental aspiration pneumonia have uncovered protective roles for RvE1 in pathogen-mediated inflammation that are both anti-inflammatory for neutrophils and protective for host defense, suggesting that RvE1 represents the first candidate for a novel therapeutic strategy for acute lung injury and pneumonia that harnesses natural resolution mechanisms.",
author = "Hiroyuki Seki and Koichi Fukunaga and Makoto Arita and Hiroyuki Arai and Hiroki Nakanishi and Ryo Taguchi and Taku Miyasho and Rina Takamiya and Koichiro Asano and Akitoshi Ishizaka and Junzo Takeda and Levy, {Bruce D.}",
year = "2010",
month = "1",
day = "15",
doi = "10.4049/jimmunol.0901809",
language = "English",
volume = "184",
pages = "836--843",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury

AU - Seki, Hiroyuki

AU - Fukunaga, Koichi

AU - Arita, Makoto

AU - Arai, Hiroyuki

AU - Nakanishi, Hiroki

AU - Taguchi, Ryo

AU - Miyasho, Taku

AU - Takamiya, Rina

AU - Asano, Koichiro

AU - Ishizaka, Akitoshi

AU - Takeda, Junzo

AU - Levy, Bruce D.

PY - 2010/1/15

Y1 - 2010/1/15

N2 - Whereas pneumonia is the most common cause of death and disability worldwide, most cases of pneumonia spontaneously resolve. Mechanisms that promote pneumonia resolution remain to be determined. Resolvin E1 (RvE1) is an endogenous mediator that displays proresolving actions in sterile inflammation. In this study, we developed a new model of aspiration pneumonia to evaluate the effect of RvE1 on acute lung injury caused by acid aspiration and subsequent bacterial challenge. Mice received hydrochloric acid into the left lung followed by the enteric pathogen Escherichia coli. I.v. administration of RvE1 (∼0.005 mg/kg) prior to acid injury selectively decreased lung neutrophil accumulation by 55% and enhanced clearance of E. coli. RvE1 significantly decreased lung tissue levels of several proinflammatory chemokines and cytokines, including IL-1β, IL-6, HMGB-1, MIP-1α, MIP-1β, keratinocyte-derived chemokine, and MCP-1, in a manner independent of the anti-inflammatory mediators IL-10 and lipoxin A4. In addition, animals treated with RvE1 had a marked improvement in survival. These findings in experimental aspiration pneumonia have uncovered protective roles for RvE1 in pathogen-mediated inflammation that are both anti-inflammatory for neutrophils and protective for host defense, suggesting that RvE1 represents the first candidate for a novel therapeutic strategy for acute lung injury and pneumonia that harnesses natural resolution mechanisms.

AB - Whereas pneumonia is the most common cause of death and disability worldwide, most cases of pneumonia spontaneously resolve. Mechanisms that promote pneumonia resolution remain to be determined. Resolvin E1 (RvE1) is an endogenous mediator that displays proresolving actions in sterile inflammation. In this study, we developed a new model of aspiration pneumonia to evaluate the effect of RvE1 on acute lung injury caused by acid aspiration and subsequent bacterial challenge. Mice received hydrochloric acid into the left lung followed by the enteric pathogen Escherichia coli. I.v. administration of RvE1 (∼0.005 mg/kg) prior to acid injury selectively decreased lung neutrophil accumulation by 55% and enhanced clearance of E. coli. RvE1 significantly decreased lung tissue levels of several proinflammatory chemokines and cytokines, including IL-1β, IL-6, HMGB-1, MIP-1α, MIP-1β, keratinocyte-derived chemokine, and MCP-1, in a manner independent of the anti-inflammatory mediators IL-10 and lipoxin A4. In addition, animals treated with RvE1 had a marked improvement in survival. These findings in experimental aspiration pneumonia have uncovered protective roles for RvE1 in pathogen-mediated inflammation that are both anti-inflammatory for neutrophils and protective for host defense, suggesting that RvE1 represents the first candidate for a novel therapeutic strategy for acute lung injury and pneumonia that harnesses natural resolution mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=76249111073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249111073&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0901809

DO - 10.4049/jimmunol.0901809

M3 - Article

VL - 184

SP - 836

EP - 843

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -